Skip to main content

COVID-19 Topic Center

CAR-T Therapies Expert Insights

First Report Managed Care
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA Health Forum, researchers examine if CAR-T therapies can…
First Report Managed Care
Gary Goldstein, business manager of the Blood and Marrow Transplant Program at Stanford Health Care, discusses the changes needed for increased CAR-T administration in the outpatient setting as well as commercial and provider concerns about the latest reimbursement news. To begin, can you tell us…
First Report Managed Care
An interview with Nicole M Trask, PharmD, a clinical consultant pharmacist at UMass Medical School and secretary of the AMCP’s Northeast Regional Affiliate. Can you the difference between gene therapy and cell therapy? I noticed that these terms sometimes get lumped together, but from what I…
First Report Managed Care
An interview with Russel J Spjut, PharmD, formulary management clinical pharmacist and consultant at Formulary Intel Consulting. It seems CAR-T therapy seems to have kind of taken managed care by surprise. From your experience what has the reaction to these approvals been? I think it was one of…
Back to Top